Advertisement
In a new job – January 14, 2025
Mikko Kemppainen has been appointed as General Counsel and Secretary to the Board of Directors of Orion Corporation, and a member of the Executive Management Board of the Orion Group as of 1 June 2025.
In a new job – January 14, 2025
The Board of Directors of Arjo and Joacim Lindoff have come to an agreement which implicates Joacim leaving his position as President & CEO of Arjo, a role he has held since 2017.
Pharma Business – January 14, 2025
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the company’s drug candidate TCP-25 for the treatment of the severe disease Epidermolysis Bullosa (EB).
Biotech Business – January 14, 2025
The U.S. Food and Drug Administration (FDA) has accepted BioArctic’s partner Eisai’s Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly maintenance dosing.
Clinical Trials – January 14, 2025
Orexo has announced positive topline results from the clinical study OX640-002.
Biotech Business – January 13, 2025
Elicera Therapeutics’ drug candidate ELC-100 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic neuroendocrine tumors.
Clinical Trials – January 14, 2025
Orexo has announced positive topline results from the clinical study OX640-002.
Clinical Trials – December 18, 2024
Hansa Biopharma has announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) and an indirect treatment comparison of the 15-HMedIdeS-09 study data to the International Guillain-Barré Syndrome Outcome Study (IGOS), a worldwide prospective study by the Inflammatory Neuropathy Consortium on prognosis and biomarkers of GBS.
Clinical Trials – December 11, 2024
Immunovia has announced the successful completion of the CLARITI study, (Clinical Validation of Next-Generation Test for Early-Stage Pancreatic Cancer) to detect early-stage pancreatic ductal adenocarcinoma (PDAC).
Clinical Trials – December 10, 2024
The first dose has been administered in the company’s Phase II clinical study evaluating the drug candidate sevuparin for the treatment of chronic kidney disease (CKD) with associated anemia.
Clinical Trials – December 3, 2024
The trial will be conducted in patients with pre-existing anti-AAV antibodies which limit use of gene therapy treatment.
Clinical Trials – November 19, 2024
Modus Therapeutics has received approval from the relevant authorities in Italy for its planned Phase IIa clinical trial with sevuparin.
Pharma Business – January 13, 2025
AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) who have received prior systemic therapies, including an EGFR-directed therapy.
Pharma Business – January 13, 2025
Diamyd Medical provides an update following the receipt of final meeting minutes from a positive Type C meeting with the U.S. Food and Drug Administration (FDA) held in December 2024.
Financing – January 9, 2025
AnaCardio has announced the completion of a USD 19 million Series A extension financing round, co-led by Novo Holdings, Pureos Bioventures and Sound Bioventures. Current investors Flerie, Industrifonden, and Fredrik and Ann-Helene Ljungström, also participated to complete the round.
Acquisition – January 6, 2025
Before Christmas Finnish Combinostics announced that it has entered an agreement with the Swedish company SyntheticMR where SyntheticMR will acquire all shares in Combinostics.
Collaboration – December 3, 2024
Capitainer plays a key role in the international AIR project (Artificial Intelligence Radiology) aimed at improving the diagnostics and monitoring of lung diseases.
Intellectual Property – December 2, 2024
The company has been granted a US patent for its SiPore platform technology.
Agreement – December 19, 2024
BioArctic has entered into a global exclusive license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-amyloid-beta antibody program, including BAN1503 and BAN2803, whereof the latter includes BioArctic’s BrainTransporter technology.
Acquisition – December 18, 2024
Ultimovacs and Zelluna Immunotherapy have announced that Ultimovacs and shareholders of Zelluna representing more than 99% of the total number of issued and outstanding shares in Zelluna have entered into a definitive business combination agreement to combine the two companies in a share exchange transaction.
Biotech Business – December 17, 2024
Orexo has entered into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology.
Science – July 8, 2024
Unfortunately genes do matter when it comes to obesity, but knowledge about these genes and how they work are key to improving treatment and prevention.
Profiles in Science – June 18, 2024
Anna Falk, Head of Lund University’s Center for Advanced Therapies (LU-ATMP) and principal researcher of the Department of Neuroscience at Karolinska Institutet (KI) shares insights into her research, her multi-faceted job, and her vision for the future of neuroscience. Anna Falk is a molecular biologist with a PhD in neural stem cells and adult neurogenesis. […]
Science – September 20, 2023
An international team of scientists led by the University of Helsinki performed comprehensive mapping of structural alterations in cellular proteins during the aging process. In the study published in Molecular Cell, the team mapped structural alterations in cellular proteins during the aging process and, in the process, identifying new ways aging impacts how cells hum […]
Diamyd
Diamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd® is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production that has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 1, 2 and 3 Type 1 Diabetes.
Stryker
The Senior Operative ensures that the Stryker products are received, stored and shipped in a professional and timely fashion with the right quality.
Stryker
Are you ready to make a real impact in healthcare? At Stryker, we’re passionate about improving patient outcomes and enhancing hospital experiences.
Stryker
Are you ready to make a real impact in healthcare? At Stryker, we’re passionate about improving patient outcomes and enhancing hospital experiences.
Stryker
Are you ready to make a real impact in healthcare? At Stryker, we’re passionate about improving patient outcomes and enhancing hospital experiences.
ArgusEye
An opportunity to use your strategic mindset and sales expertise to make a transformative impact in the biopharmaceutical industry.
In a new job – January 10, 2025
Enzymatica has announced that Anna Söderlund has joined as the new Senior Director Marketing & Sales.
In a new job – January 9, 2025
Alice Long, a leading expert in translational immunology and diabetes research, has joined Diamyd Medical’s Scientific Advisory Board (SAB).
In a new job – January 2, 2025
BerGenBio has announced the appointment of Olav Hellebø as CEO.
Careers article – January 9, 2025
Getting back to work after a long and relaxing holiday can be quite hard. Here is some advice to make things easier.
Biotech Business – December 3, 2024
Alligator Bioscience is sharpening its primary focus on its lead asset mitazalimab, and, given current capital restraints, plans to adjust the size of its organization and scope of operations to reflect that.
Biotech Business – November 26, 2024
The rightsizing is expected to result in redundancy of approximately 20 percent of the employees across the CELLINK organization.
Profiles in Business – April 23, 2024
Despite being the co-founder of Ilya Pharma and co-director at the Science for Life Laboratory (SciLifeLab), Dr. Mia Phillipson, considers herself a scientist foremost, not an entrepreneur. “Most of all, I am a scientist. Yes, absolutely. This is my main occupation and the one in which I have the most expertise,” says Mia Phillipson, who […]
Business article – April 17, 2024
Personalized medicine, weight loss remedies and new treatments for widespread ailments are among the rising areas of high interest in the biotechnology and therapeutic arenas, according to executive chairman of Flerie Invest, Thomas Eldered. Thomas Eldered talked with Nordic Life Science about the Nordic and global life science financial landscapes and Flerie’s role in funding […]
Business – November 28, 2023
The previous founder and CEO of BioLamina has gone back to business development, and with his newly founded company he aims to redefine cell therapy development even further. Newly founded Alder Therapeutics is a preclinical phase stem cell therapy development company and, according to Kristian Tryggvason, co-founder and CEO, it is “the next big thing.” […]
This site uses cookies
